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ABSTRACT: 
Of 1463 liver allograft recipients receiving the combination 
of FK506 and steroids as their primary immunosuppressive'regimen, 
two patients developed Kaposi's sarcoma. Al though previously 
described as a complication of organ transplantation, this is the 
first case report of Kaposi's sarcoma occurring in association with 
the macrolide immunosuppressive agent FK506. A discussion of the 
clinical presentation and course of Kaposi's sarcoma in these two 
patients, as well as a review of the past literature on Kaposi's 
sarcoma in organ transplant recipients, emphasizes the therapeutic 
difficulties encountered. Kaposi's sarcoma is also compared to 
lymphoproliferative disorders, another well recognized complication 
of immunosuppression, highlighting the differences between these 
two entities. 
INTRODUCTION: 
Kaposi's sarcoma is a rare multicentric neoplasm of 
controversial origin known to occur in individuals who are immune 
deficient. It is a recognized complication of organ 
transplantation, accounting for 6% of post transplant 
l ' " ma ~gnanc~esK From 1 March 1989 until 19 June 1992, a total of 
1463 liver allograft recipients have received FK506 in combination 
with steroids as their primary immunosuppressive regimen at the 
University of Pittsburgh. Approximately 10% of this population are 
foreign nationals, mainly of middle eastern extraction, in whom 
there also appears to be a genetic predisposition for Kaposi's 
sarcoma. 
The literature on Kaposi's sarcoma in organ transplant 
patients has focused mainly on renal allograft recipients in whom 
regression of the disease and patient survival do not necessarily 
equate with continued graft function (see Table I). Treatment of 
Kaposi's sarcoma has closely paralleled the approach used in post 
transplant lymphoproliferative disorders (PTLD) and the two 
entities are frequently compared. The overall prognosis for 
Kaposi's sarcoma in liver allograft recipients has, however, been 
poor with a 45% mortality rate in a series of such patients 
presented by Bismuth et al in 1991. 2 This contrasts markedly with 
the results of a recent review from the University of Pittsburgh of 
15 patients with PTLD (13 liver and 2 renal allograft recipients) 
of whom 10 (67%) have survived with functional grafts. 3 The 
following case reports describe Kaposi's sarcoma occurring in 
1 
association with FK506 immunosuppression in two liver allograft 
recipients, and serve to illustrate the therapeutic difficulties 
encountered in its clinical management. 
CASE 1 
A 49 year old Saudi Arabian man was admitted on 24 January 
1992, ten months after successful orthotopic liver transplantation 
for Laennec's cirrhosis, with a diagnosis of Kaposi's sarcoma. He 
presented with new onset dark raised purple lesions of his lower 
extremities which had recently been increasing in number. A biopsy 
of several of these lesions was performed on 17 January 1992 and 
confirmed a diagnosis of Kaposi's sarcoma. (Figure la, 1b) The 
patient's past history was significant for a portacaval shunt 
performed prior to his liver transplant, a biliary reconstruction 
performed in May 1991 for ampullary dysfunction, and chronic renal 
failure, requiring hemodialysis three times per week since August 
1991, due to glomerulonephritis and hypertension. After 
transplantation, he had experienced two episodes of acute cellular 
rejection documented by liver biopsies which were treated with a 
steroid recycle, a pulse bolus of methylprednisolone and the 
institution of azathioprine. Medications on admission consisted of 
FK506, 4 mg po bid, Prednisone 20 mg po qJday and Acyclovir 200 mq 
po bid. The serum FK506 level was 0.5 nq/ml and azathioprine had 
been stopped soon after the skin biopsy -documented the presence of 
Kaposi's sarcoma. 
On admission, FK506 was reduced to 2 mg po bid and Prednisone 
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to 5 mg po qd; a interferon at a dose of 5 million units sq qd was 
started and was increased four days later to 10 million units sq 
qd; Acyclovir was discontinued. Investigations during the 
patient's hospitalization included a CT scan of the head, chest and 
abdomen which showed a large right pleural effusion, a small 
pericardial effusion without pulmonary parenchymal lesions or 
lymphadenopathy and scattered focal areas of small bowel 
thickening. An enteroclysis study revealed a generalized 
dilatation of the small bowel with a slightly prolonged transit 
time, but no evidence for Kaposi's sarcoma. On 
esophagogastroduodenoscopy, a moderately inflamed distal esophagus 
with normal stomach and duodenum were noted; biopsies of the 
esophagus showed acute and chronic inflammation. A limited 
colonoscopy was performed which showed no colonic lesions. The 
right pleural effusion was aspirated and cytologic examination of 
the fluid revealed no malignant cells. 
Viral serologic studies sent on admission included an HIV and 
a hepatitis C screen which were negative; a hepatitis B serology 
which was negative for hepatitis B surface antigen, positive for 
anti HBs, and negative for anti HBc. Other viral titers included 
cytomegalovirus (CMV) IgG >120 (ref. value <20), negative CMV IgM, 
Epstein Barr virus (EBV) IgG >50, EBV IgM <10 and EBV nuclear 
antigen 2; herplex simplex IgG was >200 (ref. value <8) and herpes 
zoster IgM <20 (ref value <20). Immunoperoxidase, in-situ 
hybridization and polymerase chain reaction techniques failed to 
detect CMV particles within the lesions in the skin biopsy. The 
3 
HLA status of the patient was HLA - A2 A24 B35 B51 BW4 BW6 DR4 DR11 
DQW3 DRW52 DRW53. 
On a regimen of daily ainterferon therapy and reduced 
immunosuppression, the Kaposi lesions stabilized. Liver function 
however worsened, necessitating a liver biopsy on 3 February 1992, 
which showed a mixed portal inflammatory infiltrate with low grade 
lobular reactivity. The patient was given a one gram bolus of 
methylprednisolone intravenously, and his maintenance prednisone 
and FK506 were increased to 10 mg po qd and 2 mg po bid, 
respectively. The patient was discharged at his request on 
February 12, 1992. The serum FK506 level was 1.9 ng/ml and the 
Kaposi lesions of his lower extremities were unchanged. 
Medications on discharge consisted of ainterferon 10 million units 
sq daily, prednisone 10 mg once a day, and FK506 2 mg po bid. 
Two days later, the patient was readmitted with complaints of 
increasing fatigue and muscular aches. His liver function tests on 
admission had deteriorated further with a total bilirubin of 3.5 
mg/dl, a conjugated bilirubin of 3.1 mg/dl, an alkaline phosphatase 
level of 349 IU/dl, a gamma GTP of 1242 IU/dl, an SGOT (AST) of 
1145 IU/dl and an SGPT (ALT) of 938 IU/dl; the FK506 level was 
reported as 2.1 ng/ml. A liver biopsy was performed on February 
15, 1992, which revealed lobular reactivity, single cell necrosis 
and chronic bile duct injury. Immunoperoxidose staining for 
hepatitis B surface antigen was negative. Coxsackie virus titers 
were negative; autoimmune markers were negative and the erythrocyte 
sedimentation rate was 42 mm/hr. 
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On February 16, 1992, the patient developed coffee ground 
emesis and experienced a melanotic stool with a significant drop in 
his hematocrit. Esophagogastroduodenoscopy revealed prominent 
gastric varices along the greater curvature of the stomach and 
biopsies of the duodenal and gastric mucosa were negative for CMV. 
Repeat autoimmune markers were positive for thyroglobulin 
antibodies at 100 (Ref. value <100) and microsomal antibodies at 
400 (Ref. value <100). with the continued deterioration in liver 
function, an acute autoimmune hepatitis precipitated by a 
interferon was suspected and the a interferon was discontinued. 
A repeat endoscopy performed on February 20, 1992, for 
continued upper gastrointestinal bleeding demonstrated the 
continued presence of gastric varices. An arteriogram showed 
thrombosis of the midportion of the splenic vein with patent 
superior mesenteric and portal veins. An exploratory laparotomy, 
splenectomy and gastric devascularization was performed on February 
21, 1992. In the immediate postoperative period, the patient was 
stable; he tolerated extubation well and was transferred out of the 
intensive care unit on postoperative day 3. 
Ten days later, the patient redeveloped upper gastrointestinal 
bleeding necessitating endoscopy which revealed severe portal 
hypertensive gastropathy. His serum bilirubin level was markedly 
elevated at 26.3 mg/dl. On March 14, a liver biopsy was obtained 
which showed mild acute cellular rejection with marked duct damage 
and bile duct loss, as well as panlobular hepatocyte swelling and 
disarray. The patient was treated with one gram methylprednisolone 
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IV and FK506 was reinstituted at a dose of 2 mg po twice a day: 
prednisone was increased from 5 mg to 10 mg po daily. Repeat 
thyroglobulin and microsomal antibody titers were 400 and 1600 
respectively. Hepatitis B serology and the hepatitis C screen 
continued to be negative. The Kaposi lesions of the lower 
extremities were essentially unchanged. 
The patient continued to have upper gastrointestinal bleeding 
which became refractory to all resuscitative efforts: comfort 
measures were instituted and the patient expired. 
CASE 2 
A 39 year old Saudi Arabian man was admitted to the 
Presbyterian University Hospital on February 10, 1992, 4.5 months 
after an orthotopic liver transplant for cirrhosis secondary to 
hepatitis B virus infection with increasing fatigue and extensive 
mul tiple nodular dark skin lesions which had started on his 
anterior abdominal wall approximately one month prior to admission 
and had rapidly disseminated to involve the rest of his body. On 
examination, these lesions had the typical appearance of Kaposi's 
sarcoma: there was no obvious oropharyngeal involvement and no 
palpable lymphadenopathy or edema. His past history was 
significant for excision of a hemangioendothelioma involving the 
right sixth and seventh ribs on December 23, 1991. Three biopsy 
documented rejection episodes had been treated with a pulse bolus 
of intravenous methylprednisolone and a steroid recycle: the 
patient was also receiving hepatitis B immunoglobulin every three 
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to four weeks as part of a research protocol. Medications on 
admission included FK S06 8 mg po bid, prednisone 2.S mg po q day: 
acyclovir 800 mg po qid (CMV prophylaxis), Isoniazid 300 mg po q 
daily and Bactrim SS one tablet po on alternate days. The serum FK 
S06 level on admission was 1.7 ng/ml; the white cell count was 4.9 
and liver parameters included a total bilirubin 0.8 mg/dl, an SGOT 
of 60 IU/dl, an SGPT of SO IU/dl, an alkaline phosphatase of 83 
IU/dl and a gamma GPT level of 9S IU/dl. The patient's HLA status 
was HLA A2 A30 B44 BS1 BW4 DR1 DR11 DQW1 DQW3 DRWS2. 
In view of the diagnosis of Kaposi's sarcoma, FKS06 was 
reduced to 2 mg po bid and a interferon therapy was started at 10 
million units subcutaneously daily. Investigations obtained 
included: a CT scan of the head, chest and abdomen, which showed 
bilateral pleural effusions and no other evidence of disease; an 
enteroclysis study of the small bowel, which was normal; an 
esophagogastroduodenoscopy which showed multiple vascular lesions 
consistent with Kaposi's sarcoma involving the cardia, body and 
antrum of the stomach as well as the duodenum to the ligament of 
Trei tz : colonoscopic examination was normal. A biopsy of the 
gastrointestinal lesions was not obtained due to a low platelet 
count of 33000/mm3 • Serologic studies performed on admission 
included a negative HIV antibody screen: a positive hepatitis C 
screen, a positive anti-HBc and anti-HBs and an anti-delta 
hepatitis screen which was positive. other viral studies included 
a CMV IgG >120 (Ref. value <20) and EBV IgG 400, EBV IgM <10, EBV 
nuclear antigen >8 and an EBV early antigen of 10. 
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With the combination of a reduction in immunosuppression and 
continued a interferon therapy, the patient developed a progressive 
rise in his liver injury parameters ultimately requirin.g a liver 
biopsy on February 28, 1992, at which time the total bilirubin was 
0.4 mg/dl, alkaline phosphatase 132 IU/dl, gamma GPT 258 IU/dl, 
SGOT 121 IU/dl and SGPT 147 IU/dl. The biopsy showed mild acute 
cellular rejection, and the FK506 dose was increased to 2 mg po bid 
having been previously reduced to 2 mg q d; FK506 levels had been 
ranging between 0.2 - 0.4 ng/ml. 
Liver function, however continued to deteriorate despite the 
augmentation in immunosuppression. An analysis of the patient's T-
cell subsets in peripheral blood showed a rise in the number of 
natural killer cells from 7% to 12%. Autoimmune markers were sent 
and were reported as negative. In view of the fact that a 
interferon can enhance T-cell mediated cytotoxicity and augment 
natural killer cell (NK) activity, and because the size and number 
of the patient's Kaposi skin lesions had diminished suggesting a 
partial response to therapy, it was opted to reduce the a 
interferon dose to 5 million units sq per day on March 5, 1992. 
The patient's liver function continued to deteriorate however, 
and a liver biopsy obtained on March 17 showed continued mild acute 
cellular rejection, with centrilobular cholestasis and a low grade 
hepatitis. Immunocytochemical stains for hepatitis B surface and 
core antigens were negative. Isoniazid was stopped, one gram of 
methylprednisolone IV was administered, and the daily prednisone 
dose was increased to 10 mg. 
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On March 24, a interferon was reduced further to 3 million 
units sq daily and an additional one gram of intravenous 
methylprednisolone was given for a total bilirubin of 15.4 mg/dl, 
alkaline phosphatase 1264 IU/dl, SGOT 436 IU/dl, SGPT 460 IU/dl and 
Gamma GPT 1706 IU/dl. An ultrasound of the liver was essentially 
normal. 
A repeat liver biopsy obtained on March 28, showed evidence of 
chronic rejection as reflected by a paucity of bile ducts and 
prominent centrilobular cholestasis consistent with a vanishing 
bile duct syndrome. A lobular inflammatory infiltrate was present 
suggesting a low grade hepatitis. Immunocytochemical stains for 
hepatitis B surface and core antigens were again negative. All 
cytomegalovirus stains and cultures were negative. Liver injury 
parameters continued to be elevated with a total bilirubin of 17.3 
mg/dl, an alkaline phosphatase of 1293 IU/dl, SGOT of 530 IU/dl, 
SGPT of 639 IU/dl, and a Gamma GPT of 2088 IU/dl. The serum FK 506 
level was 0.9 ng/ml and a one gram intravenous bolus of 
methylprednisolone was given on April 1. The patient was 
discharged on April 4, 1992. He returned to Saudi Arabia on a 
regimen of FKS06 2 mg po bid, prednisone 10 mg po q daily, and a 
interferon 3 million units sq q daily. The Kaposi skin lesions 
have continued to decrease in size and number, but have failed to 
completely resolve. 
DISCUSSION: 
Kaposi I s sarcoma (KS) is a complex tumor of controversial 
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origin which was first described in 1872 by Moritz Kaposi. 4 It 
occurs in four different clinical settings, 5,6 each varying in its 
presentation and behavior. The original "classic" form of KS is a 
local indolent and slow growing disease of the lower extremities 
with a prevalence of 0.01 to 0.06 per 100,000 population in Europe 
and North America; it is found in greatest frequency in those of 
Mediterranean and Ashkanazi Jewish decent. 5,7 African or "endemic" 
KS usually presents with nodular lesions of the extremities which 
tend to become exophytic or ulcerative, with or without lymph node 
involvement. It forms 10% of all malignancies in Africa7 and has 
. .. . . 1 f' 6,7 a h1gher 1nc1dence 1n equator1a A r1ca. "Epidemic" KS, 
associated with the acquired immune deficiency syndrome (AIDS) is 
more aggressive with widespread multiple purple brown macules, 
papules and nodules, as well as, visceral involvement in up to 75% 
of cases (5% have only visceral involvement); it frequently 
includes lymph node involvement resulting in a lymphadenopathic 
variant. The incidence of KS in the AIDS population is 20 -
30%.7,8,9 Finally, KS can occur in immune deficiency states such as 
in organ transplant recipients and in disorders known to have a 
defect in T-Iymphocyte function such as tuberculosis, leprosy I 
systemic lupus erythematosus, chronic lymphocytic leukemia, 
angioimmunoblastic lymphadenopathy and Hodgkin's disease. 4,7 KS in 
organ transplant recipients tends to be a mixture between the 
classic and epidemic forms: of 214 cases of KS listed in the 
cincinnati Transplant Tumor Registry, 59% had local disease 
involving the skin, conjunctiva and oropharyngeal mucosa, and 41% 
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had visceral disease involving mainly the gastrointestinal tract 
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and lungs. Of the two patients presented in this report, case 2 
had visceral involvement seen on endoscopy. 
The incidence of KS appears to be higher in recipients of 
non-renal organs (4% vs. 2%}1 probably reflecting the more 
aggressive immunosuppression used in such patients. An analysis of 
the type of immunosuppression used in organ transplant recipients 
with KS showed an incidence of 8% in those receiving the 
combination of Cyclosporine A (CsA) with steroids vs. 3% in those 
receiving conventional immunosuppressive therapy consisting of 
Azathioprine or Cyclophosphamide with Prednisone (Penn 1991).' To 
date, this is the first report of KS occurring in association with 
the use of the new macrolide immunosuppressive agent FK506, which 
has 100 times the immunosuppressive potency of CsA. From 1 March, 
1989, until 19 June, 1992, a total of 1463 liver allograft 
recipients have received the combination of FK506 with steroids at 
the University of Pittsburgh; further follow-up will be needed to 
determine the long term incidence of KS within this population of 
patients. 
The origin of KS is controversial, with theories ranging from 
a reticuloendothelial origin vs. that it may arise from 
vasoformative mesenchymal cells. 4,10 On the pathogenesis of KS, 
there is epidemiologic data suggesting a genetic pre-disposition as 
opposed to theories that it may be -a tissue reaction to an 
infectious agent, such as a virus rather than an autonomous tumor. 10 
In Sardinia, where there is a high incidence of classic non-HIV 
11 
related KS, 10 Contu, et al11 reported a greater than expected 
incidence of the allele HLA DR5 in Sardinians with the disease 
(p<O. 001) • HLA DR5 has also been shown to be common in AIDS 
patients with KS. 24 Neither of the patients in this series had the 
HLA DR5 allele; both however, were Arab and were HLA A2 B51 BW4 DR 
11 DQW3 and DRW52 positive. The A2 allele has been reported, by 
Qunibi et aI, to be significantly increased in their population of 
Saudi Arabian patients with KS after renal transplantation. 9 
Arguments in favor of an infectious agent in the pathogenesis 
of KS include the fact that cutaneous anergy is frequently present 
in patients with classic KS, suggesting the possibility that a 
transmissible agent is facilitated in its colonization of dermal 
4 blood vessels. In addition, in transplant recipients, Kaposi 
lesions may regress completely or at least improve with a reduction 
. • • 2 9 12 13 14 15 16 ln lmmunosuppresslve therapy. " , , " Cytomegalovirus (CMV), 
herpes simplex types I and II (HSV I & II), polyoma virus and 
hepati tis B virus (HBV), have all been linked to KS. 2,16,17,18,19 Both 
of the patients in this report had evidence of a prior CMV 
infection with raised CMV IgG levels. There was however, no 
evidence for CMV reactivation, as demonstrated by the negative CMV 
IgM ti ters and CMV cultures. CMV nuclear antigen has been 
demonstrated in KS lesions of AIDS patients 16,19, and CMV DNA has 
been found by dot blot hybridization in cultures of KS cells from 
a renal transplant recipient. 16 Kaposi 'cells, however, have been 
shown to proliferate in tissue culture despite the disappearance of 
CMV-DNA, suggesting that CMV, in the setting of an immunosuppressed 
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state, may be required for the initiation of KS, but not its 
continued growth. 16 On the other hand, in AIDS patients with CMV 
infection, integrated CMV viral DNA has not been consistently 
detected, thus raising the question as to whether CMV exists in KS 
cells merely as a secondary invader. 19 
In 1991, Bismuth et al, reported 11 patients with KS after 
liver transplantation, of whom 7 were hepatitis B surface antigen 
positive. 2 This was from a population of 397 liver allograft 
recipients with an overall prevalence for KS of 5.2% in hepatitis 
B surface antigen positive liver recipients. 2 Hepatitis B virus 
DNA has also been isolated from tumor lesions and normal skin in an 
80 year old man with KS, who was concomitantly seronegative for 
h t · t' . 19,20 epa ~ ~s B v~rusK Both patients presented in this report were 
hepatitis B surface antigen negative, although case 2 was receiving 
hepatitis B immunoglobulin for an earlier hepatitis B virus 
infection. 
Kaposi I S sarcoma can be a ubiquitous tumor with a mode of 
spread which is multifocal and not dissimilar to that of a 
lymphoma. A parallel has been made in the past between KS and 
post-transplant lymphoproliferative disorders (PTLD). 13,21,22 Both 
occur in immunosuppressed individuals whose defense mechanisms 
against oncogenesis and/or a viral infection are impaired. 4,7,13 The 
incidence of PTLD in organ transplant recipients is increased 
relative to the general population by at least 10 fold13 , and the 
incidence of KS in transplant recipients is increased up to 400 to 
500 times that of the general population. 7 The link between 
13 
cytomegalovirus infection and KS however, has not been as 
consistent as the association of Epstein Barr virus infection with 
PTLD. 13 ,16,19 Furthermore, although both conditions have been treated 
with a reduction in immunosuppression, unlike PTLD there appears to 
be a significant number of grafts lost to rejection in KS (See 
Table I). The course of PTLD associated with FK506 was recently 
reviewed at the University of Pittsburgh where a total of 15 
patients (13 liver allograft and 2 renal allograft recipients) were 
treated by a reduction in immunosuppression and intravenous 
acyclovir therapy, 10 showed complete remission and all ten have 
retained their grafts. 3 This report stands in sharp contrast with 
the series of liver graft recipients presented by Bismuth et aI, 
who were treated for KS with a reduction in their 
immunosuppression, and experienced an overall 45% mortality rate. 2 
a Interferon was used in both patients in this case. There 
have been reports of improved results in the treatment of KS using 
a interferon (a IFN) in the AIDS populationKUIaInI~I~ It's use has 
also been reported 12 in a heart transplant and a bone marrow 
•• 15 •. • 
rec1p1ent w1th encourag1ng results. In AIDS pat1ents, a IF has 
been shown to have anti-retroviral activity as demonstrated by a 
reduction in HIV antigen levels and a rise in the number of OKT4+ 
11 8,23,24,25 ce s. In KS, a IFN is thought to exert its effect by 
inhibiting angiogenesis either by a direct effect on endothelial 
cell proliferation19,27,28 or by a dl.rect inhibition of an 
angiogenesis factor19 such as interleukin 6. 26 Most recently, it has 
been used with excellent results in cases of childhood angiomas. 28 
14 
Improvement was seen with a IFN therapy in the Kaposi lesions of 
one of the two patients in this report. The immunomodulatory 
effects of a IFN however, presented a major problem in the setting 
of reduced immunosuppression in both patients10,11,12 as manifested by 
a marked deterioration in liver function with documented cellular 
rejection by serial liver biopsies. In case 1, activation of a 
dormant autoimmune process may also have occurred and contributed 
to the liver dysfunction. 
In conclusion, KS is a disease of unclear etiology to which 
there appears to be an underlying genetic predisposition. The 
therapeutic approach in KS has closely paralleled that of PTLD, but 
with a poorer end result. The use of antiangiogenesis and 
antiviral agents such as a IFN requires further evaluation. Early 
treatment of KS using chemotherapy and radiotherapy in association 
with reduced immunosuppression needs to be studied further. 
15 
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FIGURE LEGENDS 
Figure 1a: 
Figure 1b: 
Skin biopsy from patient number 1: The dermis is 
infiltrated by interlacing bundles of spindle 
shaped cells separated by dilated capillaries. 
(Haematoxylin and eosin x 100) 
Higher magnification of the skin biopsy of patient 
number 1: The spindle shaped cells are seen 
arranged in capillary channels and are admixed with 
extravasated erythrocytes and inflammatory cells. 
(Haematoxylin and eosin x 400) 
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